Bei Akademie registrieren
Recordati, IT0003828271

Recordati stock pre-market at EUR 52.73: pharmaceutical group

Published on 10/19/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The Italian pharmaceutical company develops and commercializes medicines for common and rare diseases. At Lang & Schwarz the stock trades pre-market at EUR 52.73 on October 19, 2026.

Business model and trading context

  • Recordati develops and commercializes medicines for common and rare diseases in around 150 countries.
  • The market context is the FTSE MIB in Italy.
  • Recordati stock trades pre-market at EUR 52.73 at 8:12 a.m. CEST at Lang & Schwarz on October 19, 2026.
Moderne Pharma-Produktionsanlage mit Edelstahltanks und Glasfassade bei Tageslicht
Recordati S.p.A. (IT0003828271) betreibt moderne Pharma-Produktionsanlagen mit hochwertiger Fertigungstechnik am Firmensitz in Mailand, Italien, Illustration mit AI erstellt.

Recordati develops and commercializes medicines for people living with common diseases and rare diseases in around 150 countries, according to the company's investor-relations page. Recordati stock is at EUR 52.73 pre-market at 8:12 a.m. CEST at Lang & Schwarz on October 19, 2026.

Ahead of the Xetra open

The pre-market indication is based on the Lang & Schwarz quote. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Recordati stock.

How Recordati makes its money

Recordati earns revenue by developing and commercializing pharmaceutical medicines across common-disease and rare-disease markets. The company is listed on the Italian stock exchange. Market context: Market report FTSE MIB.

More news and analysis on Recordati stock

Disclaimer...
en | IT0003828271 | RECORDATI | boerse | 70358346 | bgmi